William R. Hiatt's guest appearances

William R. Hiatt

Podcasts360

David Hill

Neal Barnard

Mark Pimentel

Thomas Keller

Andrew Solomon

Andrew Berman

Stephanie Chung

Joel Gelfand

Matthew Robbins

Lee Crosby

Mikhail Kosiborod

Seth Gross

Rakesh Jain

Robert Klein

Monica Aggarwal

OwlTail

A new subgroup analysis of the VOYAGER-PAD trial revealed whether adding clopidogrel to the rivaroxaban and aspirin regime of a patient with peripheral artery disease (PAD) at the time of revascularization is beneficial. In this podcast, William R. Hiatt, MD, provides insight into the analysis results.The topic is one he presented about during a late-breaking clinical trial session, “The Benefit and Risk of Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease After Lower Extremity Revascularization (LER) With and Without Concomitant Clopidogrel: a Key Subgroup Analysis From VOYAGER-PAD,” at ACC.20/WCC Virtual. For more, click here: www.consultant360.com/cardiology

A new subgroup analysis of the VOYAGER-PAD trial revealed whether adding clopidogrel to the rivaroxaban and aspirin regime of a patient with peripheral artery disease (PAD) at the time of revascularization is beneficial. In this podcast, William R. Hiatt, MD, provides insight into the analysis results.<br><br>The topic is one he presented about during a late-breaking clinical trial session, “The Benefit and Risk of Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease After Lower Extremity Revascularization (LER) With and Without Concomitant Clopidogrel: a Key Subgroup Analysis From VOYAGER-PAD,” at ACC.20/WCC Virtual. For more, click here: <a href="http://www.consultant360.com/cardiology" rel="nofollow" target="_blank">www.consultant360.com/cardiology</a>

William R. Hiatt, MD, on the Practice-Guiding Results of a VOYAGER-PAD Subgroup Analysis